{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Uveal+Melanoma&page=3", "query": { "condition": "Uveal Melanoma", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 200, "total_pages": 20, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Uveal+Melanoma&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Uveal+Melanoma&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T14:16:25.727Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03068624", "title": "Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Malignant Neoplasm in the Liver", "Metastatic Uveal Melanoma" ], "interventions": [ { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Autologous CD8+ SLC45A2-specific T Lymphocytes", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2017-09-08", "completion_date": "2025-07-31", "has_results": false, "last_update_posted_date": "2024-01-25", "last_synced_at": "2026-10-13T14:16:25.727Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03068624" }, { "nct_id": "NCT01930968", "title": "Definity for Ultrasound of Intraocular Tumors", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ocular Melanoma" ], "interventions": [], "intervention_types": [], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "20 Years", "maximum_age": null, "sex": "ALL", "summary": "20 Years and older" }, "enrollment_count": 0, "start_date": "2022-02", "completion_date": "2022-06", "has_results": false, "last_update_posted_date": "2022-02-23", "last_synced_at": "2026-10-13T14:16:25.727Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01930968" }, { "nct_id": "NCT00329641", "title": "Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ciliary Body and Choroid Melanoma, Medium/Large Size", "Extraocular Extension Melanoma", "Iris Melanoma", "Metastatic Intraocular Melanoma", "Recurrent Intraocular Melanoma" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "sorafenib tosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2011-02", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2014-07-31", "last_synced_at": "2026-10-13T14:16:25.727Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00329641" }, { "nct_id": "NCT02519322", "title": "Neoadjuvant and Adjuvant Checkpoint Blockade", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous Melanoma", "Mucosal Melanoma", "Ocular Melanoma", "Stage III Acral Lentiginous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIB Uveal Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IIIC Uveal Melanoma AJCC v7", "Stage IV Acral Lentiginous Melanoma AJCC v6 and v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Stage IV Uveal Melanoma AJCC v7" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Relatlimab", "type": "BIOLOGICAL" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2016-02-02", "completion_date": "2023-01-26", "has_results": true, "last_update_posted_date": "2024-04-05", "last_synced_at": "2026-10-13T14:16:25.727Z", "location_count": 2, "location_summary": "New York, New York • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02519322" }, { "nct_id": "NCT00020267", "title": "Vaccine Therapy in Treating Patients With Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer", "Adult Soft Tissue Sarcoma", "Colorectal Cancer", "Bone Cancer", "Ovarian Sarcoma", "Melanoma", "Colon Cancer", "Rectal Cancer", "Breast Cancer", "Eye Cancer", "Uterine Sarcoma" ], "interventions": [ { "name": "interleukin-2", "type": "DRUG" }, { "name": "MAGE-12 peptide vaccine", "type": "DRUG" }, { "name": "Montanide ISA-51", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": null, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": null, "start_date": "2000-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2024-03-04", "last_synced_at": "2026-10-13T14:16:25.727Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020267" }, { "nct_id": "NCT03070392", "title": "Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Uveal Melanoma" ], "interventions": [ { "name": "IMCgp100", "type": "BIOLOGICAL" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Immunocore Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 378, "start_date": "2017-10-16", "completion_date": "2025-09-17", "has_results": true, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-10-13T14:16:25.727Z", "location_count": 23, "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 16 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03070392" }, { "nct_id": "NCT03652077", "title": "A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cervical Cancer", "Gastric Cancer", "Stomach Cancer", "Gastroesophageal Junction Cancer", "Esophageal Cancer", "Hepatocellular Carcinoma", "Melanoma", "Uveal Melanoma", "Merkel Cell Carcinoma", "Mesothelioma", "MSI", "Non-small Cell Lung Cancer", "NSCLC", "Ovarian Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Small Cell Lung Cancer", "Renal Cell Carcinoma", "RCC", "Triple-negative Breast Cancer", "Urothelial Carcinoma", "Mismatch Repair Deficiency" ], "interventions": [ { "name": "INCAGN02390", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2018-09-24", "completion_date": "2021-08-18", "has_results": false, "last_update_posted_date": "2021-11-15", "last_synced_at": "2026-10-13T14:16:25.727Z", "location_count": 4, "location_summary": "Los Angeles, California • Jackson, Mississippi • Hackensack, New Jersey + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Jackson", "state": "Mississippi" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Huntsville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03652077" }, { "nct_id": "NCT06070012", "title": "Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Uveal Melanoma" ], "interventions": [ { "name": "Tebentafusp", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Diwakar Davar", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2025-08-18", "completion_date": "2030-09-30", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-13T14:16:25.727Z", "location_count": 4, "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Columbus, Ohio + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06070012" }, { "nct_id": "NCT01925599", "title": "BAP1 Testing in Instance Choroidal Nevi or Uveal Melanoma", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Choroidal Nevi, Uveal Melanoma" ], "interventions": [], "intervention_types": [], "sponsor": "Amy C Schefler, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 133, "start_date": "2013-07", "completion_date": "2022-01", "has_results": false, "last_update_posted_date": "2021-03-26", "last_synced_at": "2026-10-13T14:16:25.727Z", "location_count": 3, "location_summary": "Houston, Texas • Katy, Texas • The Woodlands, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Katy", "state": "Texas" }, { "city": "The Woodlands", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01925599" }, { "nct_id": "NCT00406120", "title": "Validation of a Molecular Prognostic Test for Eye Melanoma", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Uveal Neoplasms", "Choroid Neoplasms", "Iris Neoplasms" ], "interventions": [ { "name": "Fine needle aspiration biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 0, "start_date": "2007-05", "completion_date": "2010-05", "has_results": false, "last_update_posted_date": "2018-06-26", "last_synced_at": "2026-10-13T14:16:25.727Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00406120" } ] }